ArticleProteomics2011
Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics.
Article in Proteomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Microdroplet Mass Spectrometry Enables Rapid and Sensitive Measurement of Glucose Homeostasis for Elucidating Mechanism of Drug Action.Analytical chemistry · 2025Article
- Review
- Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors.Scientific reports · 2021Article
- ZIC-cHILIC Functionalized Magnetic Nanoparticle for Rapid and Sensitive Glycopeptide Enrichment from <1 µL Serum.Nanomaterials (Basel, Switzerland) · 2021Article
- Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.Journal of medical virology · 2020Article
- A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.PloS one · 2020Article
- Article
- Review
- Mapping human N-linked glycoproteins and glycosylation sites using mass spectrometry.Trends in analytical chemistry : TRAC · 2019Article
- Article
- Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ-based proteomics.Oncology letters · 2018Article
- An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.Clinical proteomics · 2017Article
- Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry.Proteomics · 2016Article
- A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.Journal of proteomics · 2016Article
- Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.Theranostics · 2016Article
- Proteomics of ovarian cancer: functional insights and clinical applications.Cancer metastasis reviews · 2015Review
- A quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines.The Biochemical journal · 2015Article
- Overexpression of periostin in stroma positively associated with aggressive prostate cancer.PloS one · 2015Article
- In 2014, can we do better than CA125 in the early detection of ovarian cancer?World journal of biological chemistry · 2014Review
- Mass spectrometry-based analysis of glycoproteins and its clinical applications in cancer biomarker discovery.Clinical proteomics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Ovarian cancer is the most lethal gynecologic malignancy in adult women. The origin of epithelial ovarian tumors is both morphologically and biologically heterogeneous, and different subtypes of ovarian tumors have different clinical outcomes. In spite of the heterogeneous nature of ovarian carcinoma, the current biomarkers and treatments for this disease are not subtype-specific. To discover the molecular basis of the ovarian tumor subtypes, we analyzed extracellular glycoproteins of seven common subtypes and normal ovary tissues using quantitative glycoproteomic analysis. Glycoproteins for different ovarian tumor subtypes were identified by liquid chromatography-tandem mass spectrometry and quantitated by spectral counting and then verified by iTRAQ labeling and Western blotting. Glycoproteins uniquely expressed in different subtypes of ovarian tumors or commonly expressed in most subtypes were identified. Using Western blots, we verified that mesothelin was overexpressed in serous carcinoma and transitional-cell carcinoma, CEA5 and CEA6 were overexpressed only in mucinous carcinoma, while versican and periostin were overexpressed in most subtypes of ovarian tumors. This study presents the first proteomic characterization of different ovarian tumor subtypes. The identified glycoproteins for histological subtypes of ovarian tumors will facilitate the understanding of the molecular basis, diagnosis of ovarian tumor subtypes, and predictions for treatment responses to therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.